Bill Would Force Hospitals to Warn If They Aren't Equipped to Save Premature Babies
The legislation is in part prompted by a Wall Street Journal investigation last year that found mothers had been told no lifesaving measures were possible for their extremely premature infants, even though other hospitals nearby offered care for infants born at similar gestational ages.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
US Senate Democrats to investigate Kennedy's firing of vaccine expert panel
By Ahmed Aboulenein WASHINGTON (Reuters) -Democrats on the U.S. Senate's health committee launched an investigation on Tuesday into Health Secretary Robert F. Kennedy Jr.'s firing of all members of a Centers for Disease Control and Prevention panel of vaccine experts. Kennedy last month fired the 17 members of the CDC's Advisory Committee on Immunization Practices, which reviews vaccines approved by the Food and Drug Administration before making recommendations to the CDC on their use. Kennedy replaced them with hand-picked advisers including anti-vaccine activists. "The harm your actions will cause is significant. As your new ACIP makes recommendations based on pseudoscience, fewer and fewer Americans will have access to fewer and fewer vaccines," Democrats on the Senate's Health, Education, Labor and Pensions Committee wrote to Kennedy in a letter reviewed by Reuters. A spokesperson for Senator Bernie Sanders said committee Democrats launched the investigation after Senator Bill Cassidy, the committee's Republican chairman, denied his call for a bipartisan investigation. Cassidy's office did not immediately respond to a request for comment. Democrats requested Kennedy provide information on the firings by August 12, including details of the alleged conflict of interest for each fired member and note how they differ from ones they previously disclosed. Kennedy said at the time that he fired the committee because it was rife with conflicts, but provided no specific evidence of conflicts among any departing members. They requested that Kennedy outline everyone involved in the firing decision within and out of government, asking about the role played by specific individuals, including Lyn Redwood, the former leader of an anti-vaccine group founded by Kennedy. Redwood led a presentation at the newly constituted ACIP's first meeting. The Democratic senators asked who approved the meeting agenda and who selected Redwood as presenter. They asked for all communications and documents on the appointment of the new members, including selection criteria, the vetting process, and proof they complied with government ethics requirements. "As you give a platform to conspiracy theorists, and even promote their theories yourself, Americans will continue to lose confidence in whatever vaccines are still available," the senators wrote. Kennedy said the firings were to restore public confidence in vaccines. "Millions more lives are at risk from vaccine-preventable diseases if you continue to undermine vaccine access through ACIP," said the letter, which in addition to Sanders was signed by Senators Tim Kaine, Maggie Hassan, John Hickenlooper, Ed Markey, Andy Kim, Lisa Blunt Rochester and Angela Alsobrooks.
Yahoo
3 hours ago
- Yahoo
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@
Yahoo
3 hours ago
- Yahoo
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a rare condition called Duchenne muscular dystrophy — to patients who can walk. U.S. shipments to patients who cannot walk independently are still halted, following the death of two teenage boys earlier this year. These incidents brought heightened regulatory scrutiny to Sarepta in recent weeks, while the pause of shipments raised concerns about the future of Elevidys — the company's largest revenue generator. Sarepta's announcement followed the U.S. Food and Drug Administration's recommendation that the voluntary hold on shipments be removed after a probe showed the death of an 8-year-old boy in Brazil was not related to Elevidys. Wall Street analysts said the resumption of shipments would allow Sarepta to fulfill its near-term payments to partner Arrowhead and maintain access to its debt facilities. "The FDA's recommendation and the resumption of commercial treatment in the U.S. virtually eliminate the risk of Elevidys being formally withdrawn from the market," said William Blair analyst Sami Corwin. While the decision allows some patients to regain access to the treatment, analysts warned that patients and doctors could show hesitancy in light of the recent hit to reputation. "It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term," Corwin said. Sarepta's partner Roche had also stopped Elevidys shipments in certain countries outside the U.S. Shares of Sarepta surged 36% to $18.85 in premarket trading. They have fallen more than 80% since the first Elevidys-related death was reported in March. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
